Centene CORP 8-K filings

Centene Corporation announced its intention to redeem $500 million of its 4.25% Notes due December 15, 2027, with approximately $568.66 million remaining outstanding.

Centene Corporation announced the appointment of Theodore Pienkos as Corporate Controller and Chief Accounting Officer, while Kate Casso transitions to Senior Vice President, Finance Operations and Innovation.

Centene Corporation's senior management will reaffirm its 2026 full year GAAP and adjusted diluted EPS guidance during investor meetings this week.

Centene Corporation will present at the UBS 2025 Global Healthcare Conference, reaffirming its full year 2025 financial forecasts including a diluted loss per share not to exceed $(12.85) and adjusted diluted EPS of at least $2.00.

Centene Corporation reported a GAAP diluted loss per share of $(13.50) for the third quarter of 2025 due to a $6.7 billion goodwill impairment, while simultaneously raising its full-year adjusted diluted EPS forecast to at least $2.00.

Centene Corporation announced its business and financial results through August are consistent with its full year 2025 adjusted diluted EPS forecast of approximately $1.75.

Centene Corporation announced the resignation of Director Thomas R. Greco, effective August 22, 2025, due to increased professional responsibilities.

Centene Corporation announced the immediate resignation of Director Wayne S. DeVeydt, which was not due to any dispute, leading to a reduction in the Board's size to ten directors.

Centene Corporation announced a significant loss for the second quarter of 2025, driven by increased medical costs and a reduction in Marketplace risk adjustment revenue estimates, despite strong revenue growth.

Centene Corporation has withdrawn its 2025 GAAP and adjusted diluted earnings per share guidance, citing a preliminary estimated $1.8 billion reduction in Marketplace risk adjustment revenue and a $2.75 adjusted diluted EPS impact, alongside rising Medicaid medical costs.

Centene Corporation held its Annual Meeting on May 13, 2025, and announced the results of voting on director elections, executive compensation, auditor ratification, a stock incentive plan, and shareholder proposals related to climate change.

Centene Corporation reaffirms its full-year 2025 GAAP and adjusted diluted EPS guidance during a meeting with investors.

Centene Corporation announces a 28% increase in adjusted diluted EPS for Q1 2025 and raises its full-year premium and service revenues guidance by $6 billion.

Centene Corporation reaffirms its previously issued 2025 adjusted diluted earnings per share (EPS) annual guidance of greater than $7.25 during a presentation at the Barclays 27th Annual Global Healthcare Conference.

Centene Corporation entered into a new $6 billion credit agreement, replacing its existing credit facility and refinancing outstanding debt.

Centene Corporation reaffirms its 2025 full-year adjusted diluted earnings per share (EPS) guidance floor of greater than $7.25 during investor meetings.

Centene Corporation appoints Kenneth Y. Tanji to its Board of Directors, effective February 20, 2025, expanding the board to 12 members.

Centene Corporation announces its 2024 financial results, highlighting a 7% increase in adjusted diluted EPS and raising its 2025 premium and service revenues guidance by $4.0 billion.

Centene Corporation has released its 2025 financial guidance, projecting adjusted diluted EPS of greater than $7.25, and reaffirmed its 2024 adjusted diluted EPS guidance of greater than $6.80.

Centene Corporation's senior management team reaffirmed their 2024 full-year adjusted diluted earnings per share guidance of greater than $6.80 and expects to grow adjusted diluted EPS in 2025 and beyond.

Centene Corporation's President, Kenneth J. Fasola, will retire on July 1, 2025, after a 40-year career in healthcare.

Centene Corporation announced its third quarter 2024 financial results, reporting a diluted EPS of $1.36 and adjusted diluted EPS of $1.62, while reaffirming its full-year adjusted diluted EPS guidance.

Centene Corporation reports a substantial increase in Medicare Advantage membership enrolled in plans rated 3.5 stars or higher, rising from 23% to approximately 46% year-over-year.

Centene Corporation has amended its previous 8-K filing to include the committee assignments for newly appointed board member Thomas R. Greco.

Director Lori J. Robinson has decided not to seek re-election to the Centene Corporation board when her term expires at the 2025 Annual Meeting.

Centene Corporation reaffirms its full-year 2024 adjusted diluted earnings per share guidance of greater than $6.80 ahead of investor meetings and a conference presentation.

Centene Corporation reaffirms its full-year 2024 adjusted diluted EPS guidance of greater than $6.80, while also noting a shift of 20 to 30 cents of EPS from Q3 to Q4.

Centene Corporation has appointed Thomas Greco to its Board of Directors, effective August 9, 2024, increasing the board size to 11 members.

Centene Corporation announced a 15% increase in adjusted diluted EPS to $2.42 for the second quarter of 2024, driven by Marketplace growth and cost management, while reaffirming its full-year adjusted EPS guidance.

Centene reports a $0.7 billion net outperformance from the final 2023 risk adjustment, leading to increased 2024 earnings estimates.